Pharmaceutical Executive
Espacio Riesco has adapted to the needs of pharma companies with the largest event space in Chile
The buzz of renewed pharmaceutical and healthcare sectors has extended beyond the direct activities of pharma companies and been spilt over to the service providers who are quickly adapting themselves to cater to the new and improved industry. A notable example of adaptation to the needs of pharma companies is that of the largest event space in the country, Espacio Riesco. Sergio Gutierrez, general manager of Espacio Riesco, describes that "we built this space in order to address the need for large congresses and conferences in the country and we began our operations by organizing the International Gynecology Congress at which we received more than 7,000 delegates. We are now counting with 180,000 square meters in total, out of which approximately 40,000 square meters are covered, which makes us the biggest multipurpose venue in the country. In this regard, we now have the capacity to accommodate 8,500 people for a sit-down dinner and not only for fairs and conferences." The conference center has its own in-house services for options such as catering and decoration, and is increasingly host to a number of pharmaceutical events. Gutierrez offers his vision for the future of Espacio Riesco by asserting that "we want to consolidate ourselves as the leader in the market of fairs, conferences, congresses and big corporate events."
Sergio Gutierrez, Espacio Riesco General Manager
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.